CPT2 and cancer: In contrast, in patients with gastrointestinal cancers that were poorly treated with oxaliplatin, the combination of perhexiline, an inhibitor of CPT2, and oxaliplatin was able to significantly reduce cancer cell survivability from chemotherapy via the ROS/NFATc3/CPT2 axis [94].